NCDR ACTION Registry: los pacientes anticoagulados no tienen mayor riesgo de sangrado en los procedimientos de urgencia

NCDR ACTION Registry: Anticoagulated Patients with No Higher Risk of Bleeding in Emergency Procedures

Patients with a history of atrial fibrillation treated with warfarin or any of the new direct oral anticoagulants undergoing acute myocardial infarction do not present higher risk of bleeding when receiving angiography or angioplasty. In fact, this subgroup of anticoagulated patients showed lower in-hospital mortality than the control group. After analyzing 6471 patients undergoing ST elevation MI<a href="https://solaci.org/en/2017/11/16/ncdr-action-registry-anticoagulated-patients-with-no-higher-risk-of-bleeding-in-emergency-procedures/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with atrial fibrillation undergoing PCI seemed never-ending until the RE-DUAL PCI trial was published in the New England Journal of Medicine (NEJM). This study has arrived to simplify the tough choice between the risk of a thrombotic event vs. the risk of bleeding with a simpler scheme, without<a href="https://solaci.org/en/2017/11/08/the-end-of-aspirin-for-anticoagulated-patients-undergoing-pci/" title="Read more" >...</a>

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related<a href="https://solaci.org/en/2017/11/06/tct-2017-prevail-final-outcomes-of-the-watchman-device/" title="Read more" >...</a>

Se publicaron los resultados del estudio RESPECT con excelentes novedades

Long-term results of the RESPECT study favor closure with the Amplatzer device

Courtesy of Dr. José Álvarez. The RESPECT trial is a multicenter randomized trial with blinded adjudication of end-point events. It randomly assigned patients from 18 to 60 years of age who had a patent foramen ovale (PFO) and a history of cryptogenic ischemic stroke to undergo closure of the PFO with the Amplatzer device plus medical<a href="https://solaci.org/en/2017/09/15/long-term-results-of-the-respect-study-favor-closure-with-the-amplatzer-device/" title="Read more" >...</a>

Polymer-Free DES Also Show Efficacy in Anticoagulated Patients with High Risk for Bleeding

Patients who receive chronic anticoagulation therapy and then undergo angioplasty are frequently discharged on a triple anti-thrombotic scheme that usually includes aspirin, clopidogrel, and warfarin. The optimal duration of this indication remains unclear, particularly for patients at high bleeding risk. According to expert consensus, patients receiving chronic anticoagulation may receive from 1 to 12 months of dual<a href="https://solaci.org/en/2017/09/08/polymer-free-des-also-show-efficacy-in-anticoagulated-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at ESC 2017. The traditional triple anti-thrombotic scheme with dual antiplatelet therapy  and warfarin for patients with atrial fibrillation undergoing coronary angioplasty seems to have been left behind.   This new study showed that the combination of dabigatran with a P2Y12<a href="https://solaci.org/en/2017/09/04/re-dual-pci-anti-thrombotic-management-in-patients-with-atrial-fibrillation-and-pci/" title="Read more" >...</a>

reemplazo valvular mitral por cateter en insuficiencia mitral sintomática

Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Symptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.   This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement<a href="https://solaci.org/en/2017/01/27/transcatheter-mitral-valve-replacement-for-severe-mitral-regurgitation-a-global-study/" title="Read more" >...</a>

Transcatheter Valve Thrombosis: Predictors, Incidence, and Events

This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (assumed as leaflet thrombosis) imaging in transcatheter bioprosthesis.   This study involved 70 consecutive patients who underwent transcatheter aortic valve replacement with the Edwards SAPIEN-XT device and were subjected to follow-up at 6 months and 1 year through multislice computed tomography (CT), echocardiographic data, and<a href="https://solaci.org/en/2017/01/21/transcatheter-valve-thrombosis-predictors-incidence-and-events/" title="Read more" >...</a>

A Study on Valve Thrombosis After TAVI

This study, presented in Rome at the European Society of Cardiology Congress 2016 and published simultaneously online in the Journal of the American College of Cardiology (JACC), has identified a post-TAVI valve thrombosis rate of 7% using multidetector computerized tomography (CT). However, the vast majority of cases were completely asymptomatic.   Previous studies had shown<a href="https://solaci.org/en/2016/09/07/a-study-on-valve-thrombosis-after-tavi/" title="Read more" >...</a>

Triple Antithrombotic Scheme in AMI Patients undergoing PCI

Original Title: Outcomes of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy, a Comparison of Clopidogrel vs. Prasugrel from the TRANSLATE-ACS Study. Reference: Jackson L.R. et al. JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9. Courtesy of Dr Agustín Vecchia. In these last years, new and more powerful antiaggregants have<a href="https://solaci.org/en/2016/01/29/triple-antithrombotic-scheme-in-ami-patients-undergoing-pci/" title="Read more" >...</a>